• Tech News
    • Games
    • Pc & Laptop
    • Mobile Tech
    • Ar & Vr
    • Security
  • Startup
    • Fintech
  • Reviews
  • How To
What's Hot

Elementor #32036

January 24, 2025

The Redmi Note 13 is a bigger downgrade compared to the 5G model than you might think

April 18, 2024

Xiaomi Redmi Watch 4 is a budget smartwatch with a premium look and feel

April 16, 2024
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Facebook Twitter Instagram Pinterest VKontakte
Behind The ScreenBehind The Screen
  • Tech News
    1. Games
    2. Pc & Laptop
    3. Mobile Tech
    4. Ar & Vr
    5. Security
    6. View All

    Bring Elden Ring to the table with the upcoming board game adaptation

    September 19, 2022

    ONI: Road to be the Mightiest Oni reveals its opening movie

    September 19, 2022

    GTA 6 images and footage allegedly leak

    September 19, 2022

    Wild west adventure Card Cowboy turns cards into weird and silly stories

    September 18, 2022

    7 Reasons Why You Should Study PHP Programming Language

    October 19, 2022

    Logitech MX Master 3S and MX Keys Combo for Business Gen 2 Review

    October 9, 2022

    Lenovo ThinkPad X1 Carbon Gen10 Review

    September 18, 2022

    Lenovo IdeaPad 5i Chromebook, 16-inch+120Hz

    September 3, 2022

    It’s 2023 and Spotify Still Can’t Say When AirPlay 2 Support Will Arrive

    April 4, 2023

    YouTube adds very convenient iPhone homescreen widgets

    October 15, 2022

    Google finishes iOS 16 Lock Screen widgets rollout w/ Maps

    October 14, 2022

    Is Apple actually turning iMessage into AIM or is this sketchy redesign rumor for laughs?

    October 14, 2022

    MeetKai launches AI-powered metaverse, starting with a billboard in Times Square

    August 10, 2022

    The DeanBeat: RP1 simulates putting 4,000 people together in a single metaverse plaza

    August 10, 2022

    Improving the customer experience with virtual and augmented reality

    August 10, 2022

    Why the metaverse won’t fall to Clubhouse’s fate

    August 10, 2022

    How Apple privacy changes have forced social media marketing to evolve

    October 16, 2022

    Microsoft Patch Tuesday October Fixed 85 Vulnerabilities – Latest Hacking News

    October 16, 2022

    Decentralization and KYC compliance: Critical concepts in sovereign policy

    October 15, 2022

    What Thoma Bravo’s latest acquisition reveals about identity management

    October 14, 2022

    What is a Service Robot? The vision of an intelligent service application is possible.

    November 7, 2022

    Tom Brady just chucked another Microsoft Surface tablet

    September 18, 2022

    The best AIO coolers for your PC in 2022

    September 18, 2022

    YC’s Michael Seibel clarifies some misconceptions about the accelerator • DailyTech

    September 18, 2022
  • Startup
    • Fintech
  • Reviews
  • How To
Behind The ScreenBehind The Screen
Home»Startup»Seagen vets land $4.4M for Univ. of Washington spinout using fresh approach for cancer vaccines – Startup
Startup

Seagen vets land $4.4M for Univ. of Washington spinout using fresh approach for cancer vaccines – Startup

February 7, 2023No Comments5 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Seagen vets land $4.4M for Univ. of Washington spinout using fresh approach for cancer vaccines – GeekWire
Share
Facebook Twitter LinkedIn Pinterest Email
Abacus Bioscience CEO Alan Wahl (left) and chief scientific officer Che-Leung Law. (Abacus Photo)

A biotech startup spun out of the University of Washington and led by veterans of Seattle-area biotech giant Seagen has raised $4.4 million, part of an ongoing seed round.

The leaders of the startup, Abacus Bioscience, say they’ve landed on a new, potentially powerful approach to create vaccines to treat people with cancer.

Anti-tumor vaccines have been tested for decades and some are approved, but they have shown limited effectiveness.

“’Cancer vaccine’ was a very dirty term in the investment community for a long time,” said Che-Leung Law, Abacus chief scientific officer and co-founder. “Even today, people still have a lot of skepticism about the ‘cancer vaccine approach.’”

Abacus is taking a novel approach to targeting tumor antigens, molecules on the surface of cancer cells. Its experimental agents have shown potential to generate a strong immune response to such antigens, thereby prompting tumor killing, said Law.

Law and co-founder Alan Wahl, CEO, have faced skepticism before.

They were both early employees of Seattle-area biotech giant Seagen, previously called Seattle Genetics. The company was pioneering a new type of therapy called an antibody-drug conjugate, which delivers a toxin to cells via a linked antibody. Law said when he went to give presentations, “people would just look at us and tell us ‘you guys are crazy.’”

Seagen is now a $25 billion company with four approved drugs and its approach forms the basis of multiple other companies.

Law is hopeful that Abacus is on the cusp of another field-changing technology. The name Abacus is a play on “Ab”, shorthand for “antibody.”

Abacus’ approach is to link a tumor antigen to an antibody fragment that recognizes a molecule, called CD180, on key immune cells. The agent activates the immune cells, which orchestrate a powerful immune response against the antigen. The net effect is, ideally, an immune onslaught against the tumor.

See also  Contract lifecycle management startup SirionLabs raises $25M – Startup

The approach can also be used against viruses and was tested by the company in unpublished primate studies against Hepatitis B virus. The data showed strong antibody and T cell responses, which are both needed for a strong immune effect, said Wahl.

The early studies were performed in the lab of co-founder and company chairman Edward Clark, emeritus professor of microbiology and immunology at the University of Washington. They were funded in part by a $400,000 small business grant from the U.S. government as well as grants from UW’s CoMotion and Washington state’s Life Sciences Discovery Fund.

“We had this idea a while ago,” said Wahl, who co-founded the company in 2015. “But over the years we generated really solid proof-of-concept data that this was going to work before we went forward and asked others for money to drive it forward.” The data were critical to sell a new approach to investors during the current lull in biotech financing, he said.

The debut of several successful immunotherapy approaches also shifted Law’s own view of the potential of cancer vaccines. These include immunotherapy drugs like the “checkpoint inhibitor” Keytruda; cell therapy approaches like CAR T cells; and data showing the effectiveness of antibody-drug conjugates combined with checkpoint inhibitors.

All of these approaches amplify or augment existing anti-tumor immunity. If they work, then it should be possible to build a highly effective cancer vaccine, reasoned Law.

Law was previously senior vice president of translational medicine at Harpoon Therapeutics, a San Francisco-based immunotherapy startup. Prior to that he was at Seagen for 16 years, most recently as senior director of preclinical research.

See also  The ripple effects from the Silicon Valley Bank fiasco on startups and investors – Startup

Wahl has served as a consultant to biopharma companies for the last seven years and was previously vice president of discovery at Ambrx and held research leadership roles at AbbVie, Biogen Idec, Trubion Pharmaceuticals, and Bristol Myers Squibb. At Seattle Genetics, he was senior director of molecular oncology and immunology.

Clark was also the co-founder of Genetic Systems, an early Seattle biotech company bought by Bristol Myers Squibb in 1986, and of Trubion, which was acquired for at least $96.8 million in 2010.

The other Abacus co-founders include Raj Dua, an executive at Vincerx Pharma who held leadership roles at Trubion and Seattle-area Alder Biopharmaceuticals, which was bought by Lundbeck for nearly $2 billion; and Craig Philips, president of Seattle biotech company Kineta and founding partner of Pack Ventures, a firm that funds companies connected to the UW, which participated in the funding round.

Abacus is in the process of signing a lease for lab space in Seattle and is hiring immunologists and other scientists.

The startup is currently generating agents against two tumor antigens, one found on a variety of solid tumor types and another on cervical and head and neck cancers. Researchers will test various agents in test tubes, cells and rodents before moving into primates. The company is also using new protein analysis and engineering tools, including DeepMind’s AlphaFold, to create its vaccines.

Abacus’ approach is similar to others that link antigens to a different antibody fragment, directed against a molecule called CD40. Abacus’ agents may yield a broader immune response with fewer side effects, said Law. CD40 is found on cells other than immune cells so agents directed against it can have toxicity, he said.

See also  How To Create A Scalable Solution For Multiple Client Web Design Needs

Washington Research Foundation is leading the funding round. In addition to Pack Ventures, participants are Alexandria Venture Investments, Sahsen and individual investors. 



Source link

4.4M approach cancer fresh land Seagen spinout Startup Univ vaccines vets Washington
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Multiple Milestones As New Majority Capital Boosts Entrepreneurship Through Acquisition

September 26, 2023

Getty Images Plunges Into the Generative AI Pool

September 26, 2023

3 Hot Startup Opportunities In Augmented Reality

September 26, 2023

The ChatGPT App Can Now Talk to You—and Look Into Your Life

September 25, 2023
Add A Comment

Comments are closed.

Editors Picks

Yakuza developer RGG Studio is hosting a livestream next week, but hasn’t said what it will show

September 12, 2022

Ford recalls more than 100,000 Mavericks, Escapes, and Corsairs over fire risk

July 10, 2022

The Last of Us Part I review – A PS5 remake that shines above most

September 1, 2022

Take a look at which Pacific Northwest startups are shifting up the rankings – Startup

July 14, 2022

Subscribe to Updates

Get the latest news and Updates from Behind The Scene about Tech, Startup and more.

Top Post

Elementor #32036

The Redmi Note 13 is a bigger downgrade compared to the 5G model than you might think

Xiaomi Redmi Watch 4 is a budget smartwatch with a premium look and feel

Behind The Screen
Facebook Twitter Instagram Pinterest Vimeo YouTube
  • Contact
  • Privacy Policy
  • Terms & Conditions
© 2025 behindthescreen.uk - All rights reserved.

Type above and press Enter to search. Press Esc to cancel.